Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052726 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
NCT02052726: Completed Phase 1 study, sponsored by Pfizer.
NCT02052726 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 184 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (207% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02052726, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
Study Summary
This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age groups (50-64 and 65-85 years of age). The study will assess how safe and tolerable the vaccine is, and also look at subjects' immune response to the vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL placebo
- BIOLOGICAL C. difficile vaccine with adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-01-22 |
| Est. Completion | 2015-05-05 |
| Phase | Phase 1 |
What the finished NCT02052726 record still lists
NCT02052726 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (207% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02052726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02052726 about?
NCT02052726 is a clinical study titled "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.". This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age groups (50-64 and 65-85 years ...
What is the current status of trial NCT02052726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2014-01-22. Estimated completion is 2015-05-05.
What interventions are being tested in trial NCT02052726?
The interventions under investigation include: Placebo (BIOLOGICAL), placebo (BIOLOGICAL), C. difficile vaccine with adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02052726?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02052726's enrollment target sits among peer trials
184 294th of 2000 higher than 1,704 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI